These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30593567)

  • 1. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.
    Chen Q; Cevher MA; Jiang Q; Wang S; Sun X; Roeder RG; Chen M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(42):e2213718119. PubMed ID: 36215477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
    Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
    Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
    Chen Z; Shao YL; Wang LL; Lin J; Zhang JB; Ding Y; Gao BB; Liu DH; Gao XN
    Oncogene; 2021 Jun; 40(22):3786-3798. PubMed ID: 33958724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
    Gardini A; Cesaroni M; Luzi L; Okumura AJ; Biggs JR; Minardi SP; Venturini E; Zhang DE; Pelicci PG; Alcalay M
    PLoS Genet; 2008 Nov; 4(11):e1000275. PubMed ID: 19043539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
    Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
    Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
    Tian Y; Wang G; Hu Q; Xiao X; Chen S
    J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
    Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
    Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pontin is a critical regulator for AML1-ETO-induced leukemia.
    Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
    Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia.
    Duque-Afonso J; Veratti P; Rehman UU; Herzog H; Mitschke J; Greve G; Eble J; Berberich B; Thomas J; Pantic M; Waterhouse M; Gentile G; Heidenreich O; Miething C; Lübbert M
    Int J Cancer; 2024 Dec; 155(11):2068-2079. PubMed ID: 39146497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
    Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.